Prognostic impact of t(9;11) in childhood acute myeloid leukemia (AML)

Nigro, Luca Lo; Bottino, Daria; Panarello, Claudio; Morerio, Cristina; Mirabile, Elena; Rapella, Anna Maria; Cataldo, Andrea Di; Schilirò, G

doi:10.1038/sj.leu.2402846

Cited by 7 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Swansbury GJ et al, showed that the best outcome was for patients aged 1-9 yr, with low WBC, and with absence of central nervous system disease or presence of trisomy 8 (85). Translocation t(9;11)(p22;q23) associated with additional chromosomal aberrations and ⁄ or a FAB subtype different from M5 could be considered as an adverse prognostic factor (82,88,89). t(6;11)(q27;q23) t(6;11)(q27;q23) has been mainly found in AML-M5 and M4 and was associated with a poor prognosis.…”

Section: The T(11q23) ⁄ Mllmentioning

confidence: 99%

Cytogenetics of pediatric acute myeloid leukemia

Manola

2009

European J of Haematology

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease accounting for 15–20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. This article focuses on the significance of cytogenetic analysis in pediatric AML supporting the importance of cytogenetic analysis in the pathogenesis, diagnosis, prognosis, follow‐up and treatment selection in childhood AML. It reviews in detail the types and frequencies of most common chromosomal aberrations, their molecular background, their correlation with French American British (FAB) subtypes and age distribution and their prognostic relevance. It also summarizes some less frequent or rare chromosome aberrations in which the prognostic classification has not been determined yet owning to the small number of patients and the variable treatment modalities used in different study groups. Furthermore, it discusses the association of specific chromosome rearrangements with prenatal exposure to carcinogenic agents or therapeutic agents and highlights the ongoing and future research on pediatric AML in the evolving field of Cytogenetics.

show abstract

Section: The T(11q23) ⁄ Mllmentioning

confidence: 99%

Cytogenetics of pediatric acute myeloid leukemia

Manola

2009

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Генетичні дослідження, проведені нами у представлених дітей, виявили моносомію 7 та t (9,11). За повідомленнями частини дослідни ків, пацієнти з такими генетичними змінами мають поганий прогноз, вони частіше є рези стентними до лікування, схильні до рецидивів, навіть після ало ТГПСК [11,31]. Також зустрі чаються публікації, де пацієнти з ГМЛ і t (9,11) мали добрий прогноз перебігу хвороби [55].…”

Section: результати дослідження та їх обговоренняunclassified

“…За даними абсолютної більшості публікацій, єдиним, проте не завжди успішним, шансом на одужання у випадку t MDS/t AML є ало ТГПСК [1,2,4,20,31,34,63,66].…”

Section: результати дослідження та їх обговоренняunclassified

Untitled

Kramarov¹,

Zakordonets²

2018

View full text Add to dashboard Cite

Внимание! Подписаться на журнал «Современная педиатрия» Вы можете во всех отделениях связи УкраиныПодписной индекс 09850 НАЦИОНАЛЬНАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ ПОСЛЕДИПЛОМНОГО ОБРАЗОВАНИЯ ИМЕНИ П.Л. ШУПИКА УКРАИНСКИЙ ИНСТИТУТ СТРАТЕГИЧЕСКИХ ИССЛЕДОВАНИЙ МЗ УКРАИНЫ БАХТИЯРОВА Д.О. Главный редактор Бережной В.В., доктор мед. наук, профессор кафедры педиатрии №2 НМАПО имени П.Л. Шупика Валиулис А. (Литва), Профессор, Генеральный директор клиники астмы, аллергии и хронических заболеваний легких, Генеральный директор EduCom (последипломное образование), Член Исполнительного комитета и казначей Европейской академии педиатрии (EAP / UEMS SP) Главный научный консультант Антипкин Ю.Г., академик НАМН Украины, директор ГУ «ИПАГ НАМН Украины» Заместители главного редактора Маменко М.Е., доктор мед. наук, профессор кафедры педиатрии №2 НМАПО имени П.Л. Шупика Волосовец А.П., чл. корр. НАМН Украины, доктор мед. наук, профессор, зав. кафедрой педиатрии №2 НМУ имени А.А. Богомольца

show abstract

“…While the National Comprehensive Cancer Network guidelines labeled t(9;11)-positive AML as an intermediate-risk disease, many studies confirmed an aggressive clinical course for this biologic entity. 2,3 In the following case, the biologic mimicry between t(9;11)-positive AML and juvenile myelomonocytic leukemia (JMML) lent t(9;11)-positive AML a peculiar adverse prognostic feature. Notably, the distortion of the clinical picture by the leukemic overlap led to a profoundly severe course due to hampering the undertaking of the correct treatment that resulted in mortality.…”

Section: Introductionmentioning

confidence: 97%

KMT2A-MLLT3 AML Masquerading as JMML may Disguise Fatal Leukemia

et al. 2019

View full text Add to dashboard Cite

We present a mortality case showcasing t(9;11)-positive acute myeloid leukemia/juvenile myelomonocytic leukemia (AML/JMML) overlap to shed light on this lethal molecular subtype of AML. In this case, the flawed assumption that JMML was to blame impeded the prompt undertaking of appropriate treatment for AML in our 14-month-old patient. This article aims to scrutinize the catastrophic sequel of such an overlap in leukemia and refutes the contemporary diagnostic methods.

show abstract

Prognostic impact of t(9;11) in childhood acute myeloid leukemia (AML)

Cited by 7 publications

References 9 publications

Cytogenetics of pediatric acute myeloid leukemia

Cytogenetics of pediatric acute myeloid leukemia

Untitled

KMT2A-MLLT3 AML Masquerading as JMML may Disguise Fatal Leukemia

Contact Info

Product

Resources

About